<2> Immunic Secures $400M to Support Late-Stage MS Trials – ICYMI
<3> Immunic’s Milestone: A Closer Look at the $400M Funding
Immunic, a clinical-stage biopharmaceutical company, has secured a significant $400 million in funding to support its late-stage multiple sclerosis (MS) trials. This substantial investment is a testament to the company’s commitment to advancing its pipeline and bringing innovative treatments to patients.
<4> The Funding Breakdown
The $400 million funding is being provided by a consortium of investors, including a prominent healthcare-focused private equity firm. This investment will be used to support the ongoing Phase III clinical trials of Immunic’s lead candidate, IMU-935, which is being developed for the treatment of relapsing-remitting MS.
<5> IMU-935: A Promising Candidate
IMU-935 is a novel, orally administered small molecule that has shown promising results in preclinical and early-stage clinical trials. The compound has demonstrated the ability to modulate the immune system and reduce inflammation in the central nervous system, which is a hallmark of MS.
<6> Market Opportunity
The MS market is a significant and growing market, with an estimated global